Italian Cell Diagnostics Company CellPly Seeded with €2M
March 21, 2014
Italy-based molecular diagnostics company CellPly has secured a €2 million ($2.8 million) seed investment from Italian Angels for Growth, Zernike META Ventures and Atlante Seed. The investment will contribute to the completion of the prototyping phase of CellPly's diagnostics platform. The company's technology platform is designed to help verify cellular response to anti-tumor drugs in-vitro (rather than directly in the patient), assisting the decisions of oncologists and doctors with predictive data.
Italy's information technology industry has received the largest portion of the total deal flow during the time period (37%) but its share has decreased each year, falling from accounting for 46% of all deals in 2011 to 32% in 2013. On the contrary, the nation's B2C industry has seen its share of the yearly deal flow increase, eventually equaling the IT industry's 32% share in 2013. The next largest portions of deal flow since the beginning of 2011 belong to Italy's B2B (21%) and healthcare (6%) industries.